New research has revealed that people taking weight loss drugs like Wegovy and Mounjaro are increasingly more likely to ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Ozempic pens being assembled at the Novo Nordisk factory in Hillerod, Denmark. (Charlotte de la Fuente for The Wall Street Journal) Shares of Europe's most valuable company rallied around 3.6% in ...

Weight loss therapeutics is a lucrative market and one that has now landed Novo Nordisk DKK65.1 billion, or more than US$10 billion, in profits – with nearly half of this from 2024 alone.

Ozempic, which accounts for 41 percent of Novo Nordisk’s sales, is an injectable treatment for diabetes that became wildly popular on social networks for its slimming properties.

Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs In a statement Monday, Novo Nordisk defended its pricing structure.

Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering and its CEO is out. Provided by Dow Jones May 16, 2025, 1:38:00 PM. By Steve Goldstein .